Alk-Abello A/S ALK-ABELLO B ORD SHS
Alk-Abello A/S ALK-ABELLO B ORD S.../ DK0061802139 /
0OIR
16/05/2024 18:36:53
|
Chg.
0.00
|
Volume |
Bid16/05/2024 |
Ask16/05/2024 |
Market Capitalization |
Dividend Y. |
P/E Ratio |
149.45DKK
|
0.00%
|
3,877 Turnover: 578,205 |
-Bid Size: - |
-Ask Size: - |
34.38 bill.DKK |
- |
102.57 |
Business description
ALK-Abelló A/S, also commonly known as ALK, is a Denmark-based pharmaceutical company which specializes in the development and manufacturing of allergy immunotherapy products for the prevention and treatment of allergy.
Management board & Supervisory board
CEO |
Carsten Hellmann |
Management board |
Claus Steensen Sølje, Søren Niegel, Henriette Mersebach |
Supervisory board |
Anders Hedegaard, Lene Skole, Gitte Aabo, Lars Holmqvist, Jesper Høiland, Bertil Lindmark, Alan Main, Katja Barnkob, Nanna Carlson, Lise Lund Mærkedahl, Johan Smedsrud |
Company data
Name: |
ALK-Abelló A/S |
Address: |
Boge Alle 6-8,Horsholm 2970 |
Phone: |
(+45) 4574 7576 |
Fax: |
(+45) 4574 8690 |
E-mail: |
reception@alk-abello.com
|
Internet: |
www.alk.net |
Industry: |
Healthcare |
Sector: |
Pharmaceutical Industry |
Sub sector: |
- |
End of financial year: |
31/12 |
Free Float: |
- |
IPO date: |
- |
Investor relations
Name: |
Per Plotnikof |
IR phone: |
+45 4574 7527 |
IR Fax: |
- |
IR e-mail: |
ppidk@alk.net
|
Company calendar
CW 34 | 23/08/2024
Interim Report 2nd Quarter/6 Months
|
CW 46 | 14/11/2024
Interim Report 3rd Quarter/9 Months
|